A. Dorum et al., RANDOMIZED STUDY OF CISPLATIN VERSUS THIOTEPA AS INDUCTION CHEMOTHERAPY IN ADVANCED OVARIAN-CARCINOMA, European journal of cancer, 30A(10), 1994, pp. 1470-1474
Between 1980 and 1984, a total of 171 patients with advanced epithelia
l ovarian carcinoma and residual tumour after surgery were randomly as
signed to treatment groups receiving either cisplatin or thiotepa. The
objective of the study was to evaluate the regimes with regard to res
ponse and survival. The two groups were well balanced with respect to
age, FIGO stage, histology, grade and residual tumour after surgery. I
n the cisplatin group, 66% responsed to treatment compared to 38% in t
he thiotepa group (P < 0.00005). The median progression-free survival
was 10.5 months and 6.3 months, respectively. The corrected survival w
as somewhat, but nonsignificantly, higher in the cisplatin group than
in the thiotepa group, with an 8-year corrected survival of 10.6 and 7
.4%, respectively. In a multivariate analysis, based on progression-fr
ee survival with FIGO stage, residual tumour after surgery, histologic
al type and grade as covariables, treatment with thiotepa had a relati
ve risk of 1.64 compared to cisplatin (95% confidence interval 1.17-2.
30, P = 0.004).